First-time surgical aortic valve replacement: nationwide trends and outcomes from The Netherlands Heart Registration

Author:

Daeter Edgar J1,de Beaufort Hector W L1ORCID,Roefs Maaike M2,van Boven Wim Jan P3,van Veghel Dennis2,van der Kaaij Niels P4, ,Bramer S,van Boven W J P,Vonk A B A,Koene B M J A,Bekkers J A,Hoohenkerk G J F,Markou A L P,de Weger A,Segers P,Porta F,Speekenbrink R G H,Stooker W,Li W W L,Daeter E J,van der Kaaij N P,Douglas Y L

Affiliation:

1. Department of Cardiothoracic Surgery, St Antonius Hospital , Nieuwegein, Netherlands

2. Netherlands Heart Registration , Utrecht, Netherlands

3. Department of Cardiothoracic Surgery, Amsterdam University Medical Center , Amsterdam, Netherlands

4. Department of Cardiothoracic Surgery, University Medical Center Utrecht , Utrecht, Netherlands

Abstract

Abstract OBJECTIVES The aim of this study was to describe trends and outcomes for patients undergoing surgical aortic valve replacement (SAVR) in the Netherlands. METHODS The Netherlands Heart Registration database was used to report the number and outcomes of isolated, primary SAVR procedures performed from 2007 to 2018 in adult patients. RESULTS A total of 17 142 procedures were included, of which 77.9% were performed using a biological prosthesis and 21.0% with a mechanical prosthesis. Median logistic EuroSCORE I decreased from 4.6 [interquartile range (IQR) 2.4–7.7] to 4.0 (IQR 2.6–6.0). The 120-day mortality decreased from 3.3% in 2007 to 0.7% in 2018. The median duration of follow-up was 76 months (IQR 53–111). Ten-year survival, when adjusted for age, EuroSCORE I and body surface area, was 72.4%, and adjusted 10-year freedom from reinvervention was 98.1%. Additional analysis for patients under the age of 60 showed no difference between patients treated with a biological or mechanical prosthesis in adjusted 10-year survival, 89.7% vs 91.9±%, respectively (P = 0.25), but a significant difference in adjusted 10-year freedom from reintervention, 90.0±% vs 95.9%, respectively (P < 0.01). CONCLUSIONS Between 2007 and 2018, age and risk profile of patients undergoing SAVR decreased, especially for patients treated with a biological prosthesis. The 120-day mortality decreased over time. Patients undergoing SAVR nowadays have a risk of 120-day mortality of <1% and 10-year freedom from valve-related reintervention of >95%.

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3